amp;#-12,)…; Physitrack Quarterly Developments; Wellness Quarterly Developments; Product-led Growth: Innovation in Action." /> amp;#-12,)…; Physitrack Quarterly Developments; Wellness Quarterly Developments; Product-led Growth: Innovation in Action." /> amp;#-12,)…; Physitrack Quarterly Developments; Wellness Quarterly Developments; Product-led Growth: Innovation in Action." />

Physitrack Limited · OMXSTO:PTRK

Physitrack — Q3 2024 Earnings Presentation

22 slides from Physitrack's earnings presentation, Nov 12, 2024

  1. Slide 1: _˓ɤΤǸʹʧ˷ʊ‫ڑ‬ ʹʔɤ‫ڑ‬Lj̇ͅ˓ɒժͣ‫ڑ‬ Ljɤ˓˓ȿɤʧ˷ʊ

    _˓ɤΤǸʹʧ˷ʊ‫ڑ‬ ʹʔɤ‫ڑ‬Lj̇ͅ˓ɒժͣ‫ڑ‬ Ljɤ˓˓ȿɤʧ˷ʊ

  2. Slide 2: Forward-looking Statement

    ‰̇ͅΨǸͅɒՑ˓̇̇ˋʧ˷ʊ‫ڑ‬ƋʹǸʹɤ˰ɤ˷ʹ ƙʔʧͣ‫̻ͅڑ‬ɤͣɤ˷ʹǸʹʧ̇˷‫ڑ‬Ɇ̇˷ʹǸʧ˷ͣ‫ڑ‬ɆɤͅʹǸʧ˷‫ڑ‬ʅ̇ͅΨǸͅɒՑ˓̇̇ˋʧ˷ʊ‫ʹͣڑ‬Ǹʹɤ˰ɤ˷ʹͣ‫ڑ‬Ǹ˷ɒ‫̻̇ڑ‬ʧ˷Ց ǸɆʹ΃Ǹ˓‫ͅڑ‬ɤͣ΃˓ʹͣջ‫ڑ‬ʧ˷Ɇ˓΃ɒʧ˷ʊ‫ʹڑ‬ʔɤ‫ڑ‬İ˰̻Ǹ˷ζլͣ‫ڑ‬ɆǸͣʔ‫ڑ‬ʅ˓̇Ψջ‫ڑ‬ʅʧ˷Ǹ˷ɆʧǸ˓‫ڑ‬Ɇ̇˷ɒʧʹʧ̇˷‫ڑ‬Ǹ˷ɒ‫ڑ‬ ʧ̇˷ͣռ‫̇ͅ‰ ڑ‬ΨǸͅɒՑ˓̇̇ˋʧ˷ʊ‫ʹͣ ڑ‬Ǹʹɤ˰ɤ˷ʹͣ‫ ڑ‬Ǹͅɤ‫ʹͣ ڑ‬Ǹʹɤ˰ɤ˷ʹͣ‫ʹ ڑ‬ʔǸʹ‫ ڑ‬ɒ̇‫ͅ ڑʹ̇˷ ڑ‬ɤ˓Ǹʹɤ‫ڑ

  3. Slide 3: Agenda

    ʊɤ˷ɒǸ ŽԒ‫ڑ‬ʧ˷‫ڑ‬Ƌʔ̇ͅʹ‫ڑ‬ A΃ͣʧ˷ɤͣͣ‫ڑ‬ƥ̻ɒǸʹɤͣ ‰ʧ˷Ǹ˷ɆʧǸ˓‫ڑ‬žɤͣ΃˓ʹͣ ƋʹͅǸʹɤʊζ‫ڑ‬Ǹ˷ɒ‫ڑ‬ŀ΃ʹ˓̇̇ˋ Ž԰ ¡ɤ˷ͅʧˋ‫ڑ‬ģ̇˓ʧ˷ IʔǸͅ˓̇ʹʹɤ‫̇̇ڑ‬ɒΨʧ˷ I_ŀ‫ڑ‬԰‫ڑ‬Ɇ̇Ցʅ̇΃˷ɒɤͅ I‰ŀ

  4. Slide 4: Q3 in Short

    ŽԒ‫ڑ‬ʧ˷‫ڑ‬Ƌʔ̇ͅʹ

  5. Slide 5: Quarterly Subscription Revenue

    ƙʔɤ‫ˋڑ̻΃̇ͅڑ‬ɤɤ̻ͣ‫˷ڑ‬ǸΤʧʊǸʹʧ˷ʊ‫ʹڑ‬ʔɤ‫ڑ‬Ɇ̇˷ʹͅǸͣʹʧ˷ʊ‫ڑ‬ĘʧʅɤɆǸͅɤ‫ڑ‬Ǹ˷ɒ‫ڑ‬Ljɤ˓˓˷ɤͣͣ‫̻ڑ‬ɤͅʅ̇ͅ˰Ǹ˷Ɇɤ‫ڑ‬Ψʔʧ˓ɤ‫ڑ‬Ɇ̇˷ʹʧ˷΃ʧ˷ʊ‫̻ͣ̇ڑʹ̻ͣ̇ڑ̇ʹڑ‬ʧʹʧΤɤ‫˷ڑ‬ɤʹ‫ڑ‬ʊ̇ͅΨʹʔռ‫ڑ‬ ԏٜ ԏԙٜ ӵԎռԓ˰ Ԑԓٜ Ž΃Ǹͅʹɤͅ˓ζ Ƌ΃ȿͣɆͅʧ̻ʹʧ̇˷ ŽԒ‫ڑ‬ԐԎԐԓ‫ڑ‬ɆǸͣʔ‫ڑ‬ʅ˓̇Ψ ɒ˃΃ͣʹɤɒ‫_ڑ‬AÅƙT‫ڑ‬ǕƙT ͅɤΤɤ˷΃ɤ‫ڑ‬ʊ̇ͅΨʹʔ ͅɤΤɤ˷΃ɤ‫ڑ‬ʊ̇ͅΨ˷ ˷ɤʊǸʹʧΤɤ ʧ˷ɆͅɤǸͣɤɒ‫̇ʹڑ‬ I΃ͅͅɤ

  6. Slide 6: Business Updates

    A΃ͣʧ˷ɤͣͣ‫ڑ‬ƥ̻ɒǸʹɤͣ

  7. Slide 7: ."$)%/+)0"-12&--)'12&-)3#4&)"-)/&''56+-1%1+2&7)%+)8#61%#'19&)+2)128$&#-12,) 71,1%#')3&#'%38#$&)7&:#27)#27)8+$6+$#%&)/…

    ."$)%/+)0"-12&--)'12&-)3#4&)"-)/&''56+-1%1+2&7)%+)8#61%#'19&)+2)128$&#-12,) 71,1%#')3&#'%38#$&)7&:#27)#27)8+$6+$#%&)/&''0&12,)83#''&2,&-; !"# D#110#++ V+#$)5,-1'&=?$,55$,&#,4$ '1$#=)5'E##$6#55D#/+* !#-"0'1'32$,'& #5)1'2#&+ C/,#-*&# H#,=5#44$,+.$#11/3/#+- 3,&#$4'5(-/'+4 !#-"0'1'32$,'& "#*16"-*&#$)&'4

  8. Slide 8: Physitrack Quarterly Developments

    ĘʧʅɤɆǸͅɤ‫ڑ‬Ž΃Ǹͅʹɤͅ˓ζ‫ڑ‬TɤΤɤ˓̻̇˰ɤ˷ʹͣ ŽԒ‫¡ڑ‬ʧʊʔ˓ʧʊʔʹͣ ԏԗٜ‫ڑ‬ʊ̇ͅΨʹʔ‫ڑ‬ʧ˷‫˓ڑ‬ʧɆɤ˷ͣɤ‫˰΃˷ڑ‬ȿɤͣͅ‫ڑ‬Ψʧʹʔʧ˷‫ڑ‬ĘʧʅɤɆǸͅɤ ŀ΃ͅ‫ ڑ‬Ŷ̇ͅɒ΃ɆʹՑ˓ɤɒ‫ ڑ‬ʊ̇ͅΨʹʔ‫ͅ ڑ‬ɤΤɤ˷΃ɤ‫ ڑ‬ʊɤ˷ɤͅǸʹʧ̇˷‫ͣ ڑ‬ʧʹͣ‫ ڑ‬Ǹʹ‫ ڑ‬ʔʧͣʹ̇ͅʧɆ‫ ڑ‬ʔʧʊʔͣ‫ ڑ‬Ψʧʹʔ‫ ڑ‬Ǹ΃ʹ̇˰Ǹʹɤɒ‫ڑ‬ ͣǸ˓ɤͣ‫ ڑ‬ʅ΃˷˷ɤ˓ͣ‫ˋ ڑ‬ɤɤ̻‫ ڑ‬ȿɤʧ˷ʊ‫ʹ̻̇ ڑ‬ʧ˰ʧͣɤɒռ‫ ڑ‬ƙʔɤ‫ ڑ‬ʧ˷Τɤͣʹ˰ɤ˷ʹͣ‫ ڑ‬ʧ˷ʹ̇

  9. Slide 9: Wellness Quarterly Developments

    Ljɤ˓˓˷ɤͣͣ‫ڑ‬Ž΃Ǹͅʹɤͅ˓ζ‫ڑ‬TɤΤɤ˓̻̇˰ɤ˷ʹͣ ŽԒ‫¡ڑ‬ʧʊʔ˓ʧʊʔʹͣ ǕƙT‫ͅڑ‬ɤΤɤ˷΃ɤջ ‫ڑ‬Ljɤ˓˓˷ɤͣͣ‫ͣڑ‬ɤʊ˰ɤ˷ʹ Ljʔʧ˓ɤ‫˷ ڑ‬ɤΨ‫ͣ ڑ‬Ǹ˓ɤͣ‫̇ ڑ‬ʅ‫ ڑ‬IʔǸ˰̻ʧ̇˷‫¡ ڑ‬ɤǸ˓ʹʔ‫˓ ڑ‬ʧɆɤ˷ͣɤͣ‫ ڑ‬ʧ˷‫ʹ ڑ‬ʔɤ‫ ڑ‬ƥĎ‫ ڑ‬ʔǸΤɤ‫ ڑ‬ȿɤɤ˷‫̇˓ ڑ‬Ψɤͅ‫ʹ ڑ‬ʔǸ˷‫ڑ‬ 2.9 ɤα̻ɤɆʹɤɒջ‫ʹڑ‬ʔɤ‫ڑ‬ī̇ͅɒʧɆ‫ͣڑ‬Ǹ˓ɤͣ‫̻ڑ‬ʧ̻ɤ˓ʧ˷ɤ‫ڑ‬ʧͣ‫ڑ‬ȿ΃ʧ˓ɒʧ˷ʊ‫˷ڑ̻΃ڑ‬ʧɆɤ˓ζ‫ڑ‬Ψʧʹʔ‫ڑ‬ʧ˷ʧʹʧǸ˓‫ڑ

  10. Slide 10: Product-led Growth: Innovation in Action

    Ŷ̇ͅɒ΃ɆʹՑĘɤɒ‫̇ͅڑ‬Ψʹʔ Å˷˷̇ΤǸʹʧ̇˷‫ڑ‬ʧ˷‫ڑ‬Ɇʹʧ̇˷ Å˷‫ڑ‬ԐԎԐԓ ջ‫ڑ‬Ψɤ‫ڑ‬ʔǸΤɤ‫ͣڑ‬ɤɤ˷‫ʹڑ‬ʔɤ‫˷̇ͅʹͣڑ‬ʊɤͣʹ‫ڑ‬ ɒɤΤɤ˓̻̇˰ɤ˷ʹ‫̇ڑ‬ʅ‫ڑ‬Ŷ̇ͅɒ΃ɆʹՑ˓ɤɒ‫ڑ‬ʊ̇ͅΨʹʔ‫ͣڑ‬ʧ˷Ɇɤ ̇΃ͅ‫ڑ‬ʔʧͣʹ̇ͅʧɆǸ˓‫ڑ‬ʔʧʊʔͣ‫̇ڑ‬ʅ‫ڑ‬ԐԎԐԎտ ‫ڑ‬ ƥ̻ɒǸʹɤɒ‫˰ڑ‬ɤͣͣǸʊʧ˷ʊ‫ڑ‬Ǹ˷ɒ‫ڑ‬ȿͅǸ˷ɒʧ˷ʊջ‫ڑ‬ɆǸʹɤͅʧ˷ʊ‫ڑ̇ʹڑ‬ Ǹ‫̇ͅ˰ڑ‬ɤ‫̻̇ͣڑ‬ʔʧͣʹʧɆǸʹɤɒ‫ڑ‬Ǹ΃ɒʧɤ˷Ɇɤ ռ‫ڑ‬ Ƌʧʊ˷Ց΃̻‫ ڑ‬ʅ΃˷˷ɤ˓

  11. Slide 11: Financial Results

    ‰ʧ˷Ǹ˷ɆʧǸ˓‫ڑ‬žɤͣ΃˓ʹͣ

  12. Slide 12: Q3 Financial Highlights

    ŽԒ‫‰ڑ‬ʧ˷Ǹ˷ɆʧǸ˓‫¡ڑ‬ʧʊʔ˓ʧʊʔʹͣ ԙ‫ʹ˷̇˰ڑ‬ʔͣ‫ͅڑ‬ɤΤɤ˷΃ɤ ԙ‫ʹ˷̇˰ڑ‬ʔͣ‫_ڑ‬AÅƙT ӵԏԐռԎ˰‫ ڑ‬ԻŽԒ‫ڑ‬ԐԎԐԒտ‫ ڑ‬ӵԏԏռԒ˰Լ Ԕٜ ӵԐռԔ˰‫ڑ‬ԻŽԒ‫ڑ‬ԐԎԐԒտ‫ ڑ‬ӵԐռԒ˰Լ ԏԎٜ ԙ‫ʹ˷̇˰ڑ‬ʔͣ‫΃ͣڑ‬ȿͣɆͅʧ̻ʹʧ̇˷‫ͅڑ‬ɤΤɤ˷΃ɤ ԙ‫ʹ˷̇˰ڑ‬ʔͣ‫ڑ‬IǸͣʔʅ˓̇Ψ ӵԙռԘ˰ՍԘԐٜ ԏԙٜ ӵԏռԙ˰‫ڑ‬ԻŽԒ‫ڑ‬ԐԎԐԒտ‫ڑڑ‬ӵԏռԓ˰Լ ԐԘٜ ԻŽԒ‫ڑ‬ԐԎԐԒտ‫ ڑ‬ӵԘռԐ˰ՍԗԐٜԼ ԙ‫ʹ˷̇˰ڑ‬ʔͣ‫ڑ‬Ǹɒ˃΃ͣʹɤɒ‫_ڑ‬AÅƙT

  13. Slide 13: Maintaining Revenue Growth

    ģǸʧ˷ʹǸʧ˷ʧ˷ʊ‫ڑ‬žɤΤɤ˷΃ɤ‫̇ͅڑ‬Ψʹʔ Footnotes: 2022 pro-forma figures represenƩ he results of Wellnow, PT Courses and Champion Health had they been acquired by the business on 1 January 2022. OrganŝĐĮŐƵres represent the current year results translated into Euro at the prevailing average exchange rates in

  14. Slide 14: Significant Growth in Subscription Revenue

    Ƌʧʊ˷ʧʅʧɆǸ˷ʹ‫̇ͅڑ‬Ψʹʔ‫ڑ‬Å˷‫ڑ‬Ƌ΃ȿͣɆͅʧ̻ʹʧ̇˷‫ڑ‬žɤΤɤ˷΃ɤ

  15. Slide 15: Adjusted EBITDA

    ɒ˃΃ͣʹɤɒ‫_ڑ‬AÅƙT 47% 2% 47% 6%

  16. Slide 16: Cash Flow

    IǸͣʔʅ˓̇Ψ Available liquidity €1.3m ӵԏռԒ˰

  17. Slide 17: Cash Flow: Impacted by Seasonal Impacts of Working Capital

    IǸͣʔՑʅ˓̇Ψ‫ڑ‬Å˰̻ǸɆʹɤɒ‫ڑ‬ȿζ‫ڑ‬ƋɤǸͣ̇˷Ǹ˓‫ڑ‬Å˰̻ǸɆʹͣ‫̇ڑ‬ʅ‫ڑ‬Lj̇ͅˋʧ˷ʊ‫ڑ‬IǸ̻ʧʹǸ˓ ԻԏԼ ‰ͅɤɤ‫ڑ‬ɆǸͣʔ‫ڑ‬ʅ˓̇Ψ‫ڑ‬ʧͣ‫ڑ‬ɒɤʅʧ˷ɤɒ‫ڑ‬Ǹͣ‫˷ڑ‬ɤʹ‫ڑ‬ɆǸͣʔ‫ڑ‬ʅ̇ͅ˰‫̻̇ڑ‬ɤͅǸʹʧ˷ʊ‫ڑ‬ǸɆʹʧΤʧʹʧɤͣջ‫˓ڑ‬ɤͣͣ‫ͅ΃̻ڑ‬ɆʔǸͣɤ‫̇ڑ‬ʅ‫ڑ‬ʧ˷ʹǸ˷ʊʧȿ˓ɤ‫ڑ‬Ǹͣͣɤʹͣ‫ڑ‬Ǹ˷ɒ‫̻̻̇ͅڑ‬ɤͅʹζջ‫˓̻ڑ‬Ǹ˷ʹ‫ڑ‬Ǹ˷ɒ‫ڑ‬ɤ́΃ʧ̻˰ɤ˷ʹ‫ڑ‬Ǹ˷ɒ‫ڑ‬ʅʧ˷Ǹ˷Ɇɤ‫ڑ‬Ɇ̇ͣʹͣռ _α̻ɤɆʹǸʹʧ̇˷‫ʹڑ‬ʔɤ‫ڑ̻΃̇ͅڑ

  18. Slide 18: Balance Sheet

    AǸ˓Ǹ˷Ɇɤ‫ڑ‬Ƌʔɤɤʹ ԒԎ‫ڑ‬Ƌɤ̻ʹɤ˰ȿɤͅ‫ڑ‬ԐԎԐԓ ԒԎ‫ڑ‬Ƌɤ̻ʹɤ˰ȿɤͅ‫ڑ‬ԐԎԐԒ _΃̇ͣͅ‫ڑ‬ժԎԎԎ ̇̇ɒΨʧ˓˓ջ‫ڑ‬ʧ˷ʹǸ˷ʊʧȿ˓ɤͣ‫ڑ‬Ǹ˷ɒ‫ڑ‬Ŷ_ ԒԓջԐԖԓ‫ڑ‬ ԒԔջԘԏԓ‫ڑ‬ IǸͣʔ‫ڑ‬Ǹ˷ɒ‫ڑ‬ɆǸͣʔ‫ڑ‬ɤ́΃ʧΤǸ˓ɤ˷ʹͣ ԔԐԐ ԓԓԎ Ȧ̇ͅͅΨʧ˷ʊͣ ԻԓջԘԔԐԼ‫ڑ‬ ԻԒջԗԘԗԼ‫ڑ‬ ƙͅǸɒɤ‫ڑ‬Ǹ˷ɒ‫ʹ̇ڑ‬ʔɤͅ‫ͅڑ‬ɤɆɤʧΤǸȿ˓ɤͣ Ԓջԙԓԓ‫ڑ‬ ԓջԓԐԘ‫ڑ‬ ƙͅǸɒɤ‫ڑ‬Ǹ˷ɒ‫ʹ̇ڑ‬ʔɤͅ‫̻ڑ‬ǸζǸȿ˓ɤͣ ԻԐջԎԘԖԼ ԻԐջԔԘԎԼ

  19. Slide 19: Strategy and Outlook

    ƋʹͅǸʹɤʊζ‫ڑ‬Ǹ˷ɒ‫ڑ‬ŀ΃ʹ˓̇̇ˋ

  20. Slide 20: Our Unique Value Proposition

    ŀ΃ͅ‫˷΃ڑ‬ʧ́΃ɤ‫ڑ‬ΤǸ˓΃ɤ‫̻̻ͣ̇̇ͅڑ‬ʧʹʧ̇˷ ¡̇˓ʧͣʹʧɆ‫̇ڑ‬ʅʅɤͅʧ˷ʊջ‫̻̇ ڑ‬Ψɤͅɤɒ‫ڑ‬ȿζ‫̻̇ʹڑ‬Ց̇ʅՑʹʔɤՑ˓ʧ˷ɤ‫ʹڑ‬ɤɆʔ ƙͅ΃ɤ‫̻̇ͅڑ‬ɒ΃Ɇʹ‫˰ڑ‬Ǹͅˋɤʹ‫ڑ‬ʅʧʹ ŶͅʧɆɤͣ‫ڑ‬ʧ˷‫ͅڑ‬ɤ˓Ǹʹʧ̇˷‫ʹڑ̇ʹڑ‬ʔɤ‫˰ڑ‬Ǹͅˋɤʹ‫ͅڑ‬Ǹʹʔɤͅ‫ʹڑ‬ʔǸ˷‫ڑ‬ʊ̇ͅΨʹʔ‫ڑ‬ɤα̻ɤɆʹǸʹʧ̇˷ͣ IǸʹɤͅʧ˷ʊ‫ڑ̇ʹڑ‬Ɇ̇˷ͣ΃˰ɤͅ‫ͅʹڑ‬ɤ˷ɒͣ Å˰̻̇ͅΤɤɒ‫̻ڑ‬Ǹʹʧɤ˷ʹ‫ʹ΃̇ڑ‬Ɇ̇˰ɤͣ‫ʹڑ‬ʔ̇ͅ΃ʊʔ‫̇ͅ˰ڑ‬ɤ‫̻ڑ‬ɤͣ̇ͅ˷Ǹ˓ʧύɤ

  21. Slide 21: How It All Comes Together

    ¡̇Ψ‫ڑ‬ʧʹ‫ڑ‬Ǹ˓˓‫ڑ‬Ɇ̇˰ɤͣ‫̇ʹڑ‬ʊɤʹʔɤͅ‫ڑ‬Ց‫ڑ‬ʧ˷Τɤͣʹʧ˷ʊ‫ڑ‬ʧ˷‫ڑ‬ŶʔζͣʧʹͅǸɆˋ ģǸͅˋɤʹ‫ڑˋ̇̇˓ʹ΃̇ڑ‬Ǹ˷ɒ‫̻ͣ̇ڑ‬ʧʹʧ̇˷ ‰̇Ɇ΃ͣ‫ͅڑ‬ɤǸͣ ¡ʧʊʔՑͅɤǸɆʔʧ˷ʊ‫ڑ‬ʅʧ˷Ǹ˷ɆʧǸ˓‫ڑ‬ʊ̇Ǹ˓ͣ ƙ̻̇Ց˓ʧ˷ɤ‫ڑ‬ʊ̇ͅΨʹʔ ŶʔζͣʧʹͅǸɆˋ‫ ڑ‬Ǹʧ˰ͣ‫ ڑ̇ʹ ڑ‬ǸɆʔʧɤΤɤ‫ ڑ‬Ǹ‫ ڑ‬ɒ̇΃ȿ˓ʧ˷ʊ‫̇ ڑ‬ʅ‫ڑ‬ ̇ͅΨʧ˷ʊ‫˰ڑ‬Ǹͅˋɤʹ‫ʹ̻̻̇ͅ΃ͣڑ‬ɤɒ‫ڑ‬ȿζ‫ڑ‬ ԏռ ģǸͅˋɤʹ‫ڑ‬ʊ̇ͅΨʹʔ‫ڑ‬ɒζ˷Ǹ˰ʧɆͣ ͅɤΤɤ˷΃ɤ‫

  22. Slide 22: Ž԰

    Ž԰

Physitrack — Q3 2024 Earnings Presentation on 6ix